Fosrenol approved in predialysis patients

Patients with chronic kidney disease and hyperphosphataemia can now be treated with Fosrenol (lanthanum carbonate) even if they have not yet started dialysis.

Alongside Alu-Cap (aluminium hydroxide) and Phosex (calcium acetate), Fosrenol is the third phosphate binder to be licensed for predialysis use.

The drug, which comes as chewable tablets, can be used in this setting when a low-phosphate diet fails to reduce serum phosphate levels below 1.78mmol/l. As lanthanum is mainly excreted in bile, monitoring of liver function is recommended.

View Fosrenol drug record

Further information: Shire

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more